Ángel Rodríguez

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

Bernhard Ludvik, Francesco Giorgino, Esteban Jódar et al. · The Lancet · 2021 · 560 citations

Once-daily Insulin Degludec, Metabolic Syndrome, Diabetes Management +11

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes

Dominik Dahl, Yukiko Onishi, Paul Norwood et al. · JAMA · 2022 · 512 citations · Full text

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó et al. · The Lancet Diabetes & Endocrinology · 2022 · 429 citations

Obesity, Metabolic Syndrome, Body Composition +12

Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort

Diego Santos‐García, T. de Deus Fonticoba, E. Suárez Castro et al. · Parkinsonism & Related Disorders · 2019 · 128 citations

Quality Of Life, Health Sciences, Psychiatry +14

Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial

Achim J. Kaasch, Luis Eduardo López-Cortés, Jesús Rodríguez‐Baño et al. · The Lancet Infectious Diseases · 2024 · 69 citations

Early Oral Switch, Healthcare-associated Infection, Patient Safety +6